Document is current
Any future updates will be listed below
-
Authors
Zhang, Jing http://orcid.org/0000-0003-1513-0695
Trojel-Hansen, Christina http://orcid.org/0000-0002-1961-3785
Wang, Jianghuang
Zhang, Zili
Wang, Xing
Qiao, Yuhui
Jiao, Huike http://orcid.org/0000-0002-5926-9130
Michaud, Mickaël
Kepp, Oliver http://orcid.org/0000-0002-6081-9558
Jäättelä, Marja http://orcid.org/0000-0001-5950-7111
Kroemer, Guido http://orcid.org/0000-0002-9334-4405
Zhong, Qing http://orcid.org/0000-0001-6979-955X
- License Information
-
More Information
Article History
Received: 21 September 2022
Revised: 9 March 2023
Accepted: 14 March 2023
First Online: 5 April 2023
Competing interests
: OK is a cofounder of Samsara Therapeutics. OK and GK have been holding research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Tollys, and Vascage. GK has been consulting for Reithera. GK is on the Board of Directors of the Bristol Myers Squibb Foundation France. GK is a scientific cofounder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. GK is in the scientific advisory boards of Hevolution, Institut Servier and Longevity Vision Funds. GK is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders. GK’ wife, Laurence Zitvogel, has held research contracts with Glaxo Smyth Kline, Incyte, Lytix, Kaleido, Innovate Pharma, Daiichi Sankyo, Pilege, Merus, Transgene, 9 m, Tusk and Roche, was on the Board of Directors of Transgene, is a cofounder of everImmune, and holds patents covering the treatment of cancer and the therapeutic manipulation of the microbiota. GK’s brother, Romano Kroemer, was an employee of Sanofi and now consults for Boehringer-Ingelheim. The funders had no role in the design of the study; in the writing of the manuscript, or in the decision to publish the results.
